Old Mission Capital’s Kazia Therapeutics KZIA Stock Holding History

Old Mission Capital’s Portfolio KZIA Stock Details KZIA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-855	Closed	-$26.3K	–	1598
2022 Q4	$26.3K	Sell	855 -763	-47%	-$28.7K	﹤0.01%	1225
2022 Q3	$89K	Buy	+1,618	New	+$181K	﹤0.01%	860

Other funds holding KZIA

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

BAM

Belpointe Asset Management Reno, Nevada $2.74B AUM 20.71% 1-Year Est. Return

NewEdge Advisors New Orleans, Louisiana $27.7B AUM 22.98% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Allworth Financial Folsom, California $24.7B AUM 15.55% 1-Year Est. Return

SPIA

Steward Partners Investment Advisory New York $19.6B AUM 22.89% 1-Year Est. Return

Advisornet Financial Minnetonka, Minnesota $1.93B AUM 18.43% 1-Year Est. Return

Old Mission Capital's KZIA Position: Q1 2023 in Review

Old Mission Capital sold out of Kazia Therapeutics (KZIA) in Q1 2023, closing a stake of 855 shares — an estimated $26.3K sold.

Old Mission Capital first reported a position in KZIA in Q3 2022 and held it in 2 quarters. The position peaked at $89K in Q3 2022. 7 funds tracked by Wall St. Rank hold KZIA as of Q1 2023.

Old Mission Capital reported no remaining Kazia Therapeutics position as of Q1 2023 after selling out during the quarter.
Old Mission Capital sold 855 Kazia Therapeutics shares in Q1 2023, an estimated $26.3K.
Old Mission Capital first reported a position in Kazia Therapeutics in Q3 2022 and held it in 2 quarters.
Old Mission Capital's Kazia Therapeutics position peaked at $89K in Q3 2022.
7 funds tracked by Wall St. Rank held Kazia Therapeutics as of Q1 2023.

Based on Old Mission Capital's 13F filing for Q1 2023, filed 12 May 2023.